<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460458</url>
  </required_header>
  <id_info>
    <org_study_id>ABB-11-01</org_study_id>
    <nct_id>NCT02460458</nct_id>
  </id_info>
  <brief_title>Type 3 Von Willebrand International Registries Inhibitor Prospective Study</brief_title>
  <acronym>3WINTERS-IPS</acronym>
  <official_title>Type 3 Von Willebrand International Registries Inhibitor Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Angelo Bianchi Bonomi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sintesi Research Srl</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Angelo Bianchi Bonomi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 5 - year International Registries and Prospective Study on VWD Type 3, aimed to assess
      number, types and risk factors for bleeding and the efficacy and safety of VWF concentrates
      used to treat VWD patients .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, characterized by
      a quantitative and/or qualitative deficiency of von Willebrand factor (VWF), that plays a
      major role in early phases of haemostasis. VWD type 3 (VWD3) is due to virtually complete
      deficiency of VWF and, for this reason, has been also described as &quot;severe VWD&quot;. VWD3 is
      inherited as a recessive trait and heterozygous relatives have mild or no bleeding symptoms.
      Even if the prevalence of VWD3 is very low, the highest rate is found in Iran and the lowest
      in southern Europe. However, the actual prevalence of VWD3 is still unknown in most
      countries, due to the lack of retrospective or prospective studies. Although rare, VWD3 is of
      major interest because of its severe clinical presentation, the need for replacement therapy
      with VWF concentrates and the risk of occurrence of anti-VWF inhibitors after the infusion of
      VWF concentrates, for which risk factors have not been systematically determined.

      The major objectives of the study are: to create an international network among European and
      Iranian Centers (ratio 1:1), the prospective enrollment of 250 VWD3 patients using a common
      database online, the collection of detailed information about previous bleedings and exposure
      to VWF concentrates, the use of bleeding severity score of VWD3 calculated with a common
      questionnaire, the evaluation of the presence of VWF gene defects with VWF phenotype and risk
      of anti-VWF inhibitors, the evaluation of anti-VWF antibody titre through common methods, the
      VWD3 gene analysis, the observation of frequency and sites of bleeding in VWD3 followed-up
      for 2 years, and the efficacy assessment of the VWF concentrates used to treat VWD3 using the
      most objective criteria for efficacy.

      To these purposes, a cohort of 250 patients with diagnosis of Type 3 von Willebrand Disease
      will be enrolled using homogenous and standardized criteria.

      The work planned to achieve the objectives of the project will be divided in three parts:

        -  the first part deals with standardized criteria for enrolment and collection of
           retrospective clinical and laboratory data, to be confirmed by centralized laboratories;

        -  the second part involves a further characterization of clinical and laboratory
           parameters, collected in the retrospective phase, including prevalence of anti-VWF
           inhibitors, advanced laboratory tests to further identify VWD3, mutations analyses of
           the VWF gene;

        -  the third part of the study for the first time deals with the prospective clinical
           observation in a large cohort of VWD3 patients all previously well characterized by an
           international panel of experts.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding Severity Score (BSS)</measure>
    <time_frame>24 months (retrospective phase)</time_frame>
    <description>The range of measurement is from -1 to +4 for each symptom considered (12 symptoms, total range from -12 to 48). For each symptom: 0=no symptom, 1=referred by the patient, 2=brought to medical attention, 3=major intervention. For spontaneous hemorrhagic symptoms, scores equal or greater than two require that the patient has specifically addressed that hemorrhagic symptom with a physician, whatever has been the diagnosis and therapy subsequently proposed. Score 0 and 1 are attributed to symptoms referred by the patient, hence without any precise medical intervention. Score 0 is for negligible or absent symptoms; 1 otherwise. For surgical procedures, it is considered important to differentiate between patients that have never bled because they never underwent surgery and those that did not bled after a surgery. These latter receive a negative score, indicating that the probability of VWD diminishes if you don't bleed after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General Laboratory Tests for VWD3 Diagnosis (Composite)</measure>
    <time_frame>36 months (retrospective + confirmatory phase)</time_frame>
    <description>Hemoglobin: (mmol/L), HT(%), MVC (fl); Leucocytes: (E9/L); Neutrophil (%); Basophil (%); Eosinophil (%); Lymphocyte (%); Platelet count: (E9/L), MPV (fl); Prothrombin Time (sec); PTT (sec); PTT mix 50:50 (sec); Ferritin (ug/l); Bleeding Time (min:sec); Closure Time (Sec); Collagen/ADP (sec); Collagen/Epinephrine (sec); FVIII:C (IU/mL); VWF:RCo (IU/mL); VWF:Ag (IU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Test for Anti-VWF Antibodies</measure>
    <time_frame>36 months (retrospective + confirmatory phase)</time_frame>
    <description>Evaluation of the titre of Anti-VWF Antibodies through Bethesda test (BU).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular Diagnosis of VWF in DNA</measure>
    <time_frame>36 months (retrospective + confirmatory phase)</time_frame>
    <description>Evaluation of the presence of VWF gene defects (confirmation or screening for the first time).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Previous Use of Blood Products</measure>
    <time_frame>24 months (retrospective)</time_frame>
    <description>Record of any product used in the previous 24 months (collected type of blood products/VWF concentrate, year of first exposure, units used).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allergic Reactions During Use of VWF-containing Concentrates</measure>
    <time_frame>24 months (retrospective)</time_frame>
    <description>Record of any allergic and anaphilactic reactions occurred in the past due to the use of any VWF concentrate and the date of onset.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Record of Bleeding Episodes</measure>
    <time_frame>24 months (prospective phase)</time_frame>
    <description>Bleeding: severity, start date, stop date; Treatment: Product name, start date, stop date, Total IU, Total ED.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months (prospective phase)</time_frame>
    <description>Record of all adverse events occurred during the prospective phase of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of VWF/FVIII-containing Concentrates in Use</measure>
    <time_frame>24 months (prospective phase)</time_frame>
    <description>Record of any VWF/FVIII-containing concentrates used and currently in use, including the current schedule type of treatment.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">266</enrollment>
  <condition>Type 3 Von Willebrand's Disease</condition>
  <arm_group>
    <arm_group_label>Type 3 VWD</arm_group_label>
    <description>Diagnosis of Type 3 von Willebrand Disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood sample, that will be used to obtain both citrated Platelet Poor Plasma for VWF
      assays and Cell Pellet for DNA extraction.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A large cohort of patients with diagnosis of Type 3 von Willebrand Disease, enrolled in
        Europe and in Iran using homogeneous and standardized criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female of any age, including infants, children, adolescent and adults

          -  Informed Consent obtained (parents should sign for patients &lt; 18 y.o.)

          -  Previous Diagnosis of VWD3 (VWF antigen: undetectable or &lt;5 U/dL)

          -  Detailed information on inherited pattern, history of bleeding, previous exposure to
             blood products

          -  Availability of plasma and DNA samples

        Exclusion Criteria:

        • VWD3 patients who may not be available for follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Augusto B. Federici, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hematology and Transfusion Medicine, L. Sacco University Hospital Department of Clinical &amp; Community Sciences, University of Milan, Via Pace, 9 20122 Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pier M. Mannucci, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Scientific Direction IRCCS Maggiore Hospital Cà Granda Foundation, Via Francesco Sforza, 28, 20122 Milan, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital, Department Internal Medicine, Coagulation Disorders, at Haematology and Laboratory Services</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut d'Hématologie - Hôpital Cardiologique - University of Lille - Haematology Department</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Régional de Traitement de l'Hémophilie - Laboratoire d'Hématologie</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Bonn - Institute of Experimental Haematology &amp; Transfusion Medicine</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital - Department of Pediatric Hematology and Oncology</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation - Hannover Medical School - Haemophilia Care Centre</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Istvan &amp; St. Laszlo Hospital of Budapest - Hematology and Stem Cell Transplantation</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ahvaz Jundishpur University of Medical Sciences - Research Center for Thalassemia &amp; Hemoglobinopathy - Division of Hematology &amp; Oncology</name>
      <address>
        <city>Ahwaz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seid-ol-Shohada Hospital - Hemophilia Center - Esfahan University of Medical Science</name>
      <address>
        <city>Esfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemophilia- Thalassaemia Center of Mashhad (Sarvar Clinic) - Mashad University of Medical Science</name>
      <address>
        <city>Mashad</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemazee Hospital Hemophilia Center - Shiraz University of Medical Science</name>
      <address>
        <city>Shiraz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iranian Hemophilia Comprehensive Treatment Centre - Iranian Hemophilia Society</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mofid Comprehensive Care Centre for Children with Hemophilia - Shahid Beheshti University of Medical Science</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thrombosis Hemostasis Research Center - Vali-Asr Hospital - Emam Khmeini Complex Hospital - Tehran University of Medical Science</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico Consorziale di Bari - Unità Operativa Semplice di Emostasi e Trombosi</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi - Agenzia per l'Emofilia - Centro di Riferimento Coagulopatie Congenite</name>
      <address>
        <city>Firenze</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Emofilia e Trombosi - Fondazione Angelo Bianchi Bonomi - IRCCS Ospedale Ca' Granda - Dip. di Medicina Interna - Università degli Studi di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Biotecnologie Cellulari ed Ematologia - Università &quot;Sapienza&quot; di Roma - Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Terapie Cellulari ed Ematologia - Centro Malattie Emorragiche e Trombotiche - Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center - Department of Hematology - Hemostasis and Thrombosis Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center - Department of Hematology</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de A Coruña - Servicio de Hematología y Hemoterapia</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari General Vall d'Hebron - Unidad de Hemofilia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz - Unidad de Hemofilia - Servicio de Hematología</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University - Centre for Thrombosis and Haemostasis - Skane University Hospital</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katherine Dormandy Haemophilia Centre and Thrombosis Unit - Royal Free Campus - University College London Medical School</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospital NHS Foundation Trust - Manchester Royal Infirmary - Manchester Royal Eye Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Iran, Islamic Republic of</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.vwd-3winters-ips.com/</url>
    <description>3WINTERS-IPS Study Website</description>
  </link>
  <reference>
    <citation>Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol. 2001 Jun;14(2):365-79. Review.</citation>
    <PMID>11686105</PMID>
  </reference>
  <reference>
    <citation>Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006 Oct;4(10):2103-14. Epub 2006 Aug 2. Review.</citation>
    <PMID>16889557</PMID>
  </reference>
  <reference>
    <citation>Nilsson IM. Commentary to Erik von Willebrand's original paper from 1926 'Hereditär pseudohemofili'. Haemophilia. 1999 May;5(3):220-1.</citation>
    <PMID>10444292</PMID>
  </reference>
  <reference>
    <citation>NILSSON IM, BLOMBACK M, BLOMBACK B. v. Willebrand's disease in Sweden; its pathogenesis and treatment. Acta Med Scand. 1959 Jun 30;164:263-78.</citation>
    <PMID>14427267</PMID>
  </reference>
  <reference>
    <citation>Mannucci PM, Bloom AL, Larrieu MJ, Nilsson IM, West RR. Atherosclerosis and von Willebrand factor. I. Prevalence of severe von Willebrand's disease in western Europe and Israel. Br J Haematol. 1984 May;57(1):163-9.</citation>
    <PMID>6609712</PMID>
  </reference>
  <reference>
    <citation>Weiss HJ, Ball AP, Mannucci PM. Incidence of severe von Willebrand's disease. N Engl J Med. 1982 Jul 8;307(2):127.</citation>
    <PMID>6979706</PMID>
  </reference>
  <reference>
    <citation>Berliner SA, Seligsohn U, Zivelin A, Zwang E, Sofferman G. A relatively high frequency of severe (type III) von Willebrand's disease in Israel. Br J Haematol. 1986 Mar;62(3):535-43.</citation>
    <PMID>3082350</PMID>
  </reference>
  <reference>
    <citation>Iorio A, Oliovecchio E, Morfini M, Mannucci PM; Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia. 2008 May;14(3):444-53. doi: 10.1111/j.1365-2516.2008.01679.x. Epub 2008 Mar 18. Erratum in: Haemophilia. 2009 Mar;15(2):637.</citation>
    <PMID>18355268</PMID>
  </reference>
  <reference>
    <citation>Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007. Ann Med. 2007;39(5):346-58. Review.</citation>
    <PMID>17701477</PMID>
  </reference>
  <reference>
    <citation>Silwer J. von Willebrand's disease in Sweden. Acta Paediatr Scand Suppl. 1973;238:1-159.</citation>
    <PMID>4550005</PMID>
  </reference>
  <reference>
    <citation>Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol. 2000 Dec;111(4):1236-9.</citation>
    <PMID>11167767</PMID>
  </reference>
  <reference>
    <citation>Federici AB, Castaman G, Mannucci PM; Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia. 2002 Sep;8(5):607-21.</citation>
    <PMID>12199668</PMID>
  </reference>
  <reference>
    <citation>Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, Casana P, De Bosch N, Eikenboom JC, Federici AB, Lethagen S, Linari S, Srivastava A. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost. 2005 Dec;3(12):2619-26. Erratum in: J Thromb Haemost. 2006 Apr;4(4):925.</citation>
    <PMID>16359502</PMID>
  </reference>
  <reference>
    <citation>Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006 Apr;4(4):766-73.</citation>
    <PMID>16634745</PMID>
  </reference>
  <reference>
    <citation>Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, Bucciarelli P. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost. 1999 Jul;82(1):35-9.</citation>
    <PMID>10456451</PMID>
  </reference>
  <reference>
    <citation>Mannucci PM, Lattuada A, Castaman G, Lombardi R, Colibretti ML, Ciavarella N, Rodeghiero F. Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease. Blood. 1989 Nov 15;74(7):2433-6.</citation>
    <PMID>2804373</PMID>
  </reference>
  <reference>
    <citation>Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. Adv Exp Med Biol. 1995;386:87-92. Review.</citation>
    <PMID>8851017</PMID>
  </reference>
  <reference>
    <citation>Federici AB. Clinical and molecular markers of inherited von Willebrand disease type 3: are deletions of the VWF gene associated with alloantibodies to VWF? J Thromb Haemost. 2008 Oct;6(10):1726-8. Review.</citation>
    <PMID>18853484</PMID>
  </reference>
  <reference>
    <citation>Veltkamp JJ, van Tilburg NH. Detection of heterozygotes for recessive von Willebrand's disease by the assay of antihemophilic-factor-like antigen. N Engl J Med. 1973 Oct 25;289(17):882-5.</citation>
    <PMID>4542316</PMID>
  </reference>
  <reference>
    <citation>Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest. 1987 May;79(5):1459-65.</citation>
    <PMID>3033024</PMID>
  </reference>
  <reference>
    <citation>Ngo KY, Glotz VT, Koziol JA, Lynch DC, Gitschier J, Ranieri P, Ciavarella N, Ruggeri ZM, Zimmerman TS. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci U S A. 1988 Apr;85(8):2753-7.</citation>
    <PMID>3258663</PMID>
  </reference>
  <reference>
    <citation>Schneppenheim R, Krey S, Bergmann F, Bock D, Budde U, Lange M, Linde R, Mittler U, Meili E, Mertes G, et al. Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet. 1994 Dec;94(6):640-52.</citation>
    <PMID>7989040</PMID>
  </reference>
  <reference>
    <citation>Eikenboom JC, Castaman G, Vos HL, Bertina RM, Rodeghiero F. Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin. Thromb Haemost. 1998 Apr;79(4):709-17.</citation>
    <PMID>9569178</PMID>
  </reference>
  <reference>
    <citation>Schneppenheim R, Castaman G, Federici AB, Kreuz W, Marschalek R, Oldenburg J, Oyen F, Budde U. A common 253-kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3. J Thromb Haemost. 2007 Apr;5(4):722-8. Epub 2007 Feb 26.</citation>
    <PMID>17371490</PMID>
  </reference>
  <reference>
    <citation>Peake IR, Liddell MB, Moodie P, Standen G, Mancuso DJ, Tuley EA, Westfield LA, Sorace JM, Sadler JE, Verweij CL, et al. Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual. Blood. 1990 Feb 1;75(3):654-61.</citation>
    <PMID>2297569</PMID>
  </reference>
  <reference>
    <citation>Mancuso DJ, Tuley EA, Castillo R, de Bosch N, Mannucci PM, Sadler JE. Characterization of partial gene deletions in type III von Willebrand disease with alloantibody inhibitors. Thromb Haemost. 1994 Aug;72(2):180-5.</citation>
    <PMID>7831648</PMID>
  </reference>
  <reference>
    <citation>Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, Mannucci PM. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost. 2000 Oct;84(4):536-40.</citation>
    <PMID>11057846</PMID>
  </reference>
  <reference>
    <citation>Mohl A, Marschalek R, Masszi T, Nagy E, Obser T, Oyen F, Sallai K, Bodó I, Schneppenheim R. An Alu-mediated novel large deletion is the most frequent cause of type 3 von Willebrand disease in Hungary. J Thromb Haemost. 2008 Oct;6(10):1729-35. doi: 10.1111/j.1538-7836.2008.03107.x. Epub 2008 Jul 28.</citation>
    <PMID>18665926</PMID>
  </reference>
  <reference>
    <citation>Xie F, Wang X, Cooper DN, Chuzhanova N, Fang Y, Cai X, Wang Z, Wang H. A novel Alu-mediated 61-kb deletion of the von Willebrand factor (VWF) gene whose breakpoints co-locate with putative matrix attachment regions. Blood Cells Mol Dis. 2006 May-Jun;36(3):385-91. Epub 2006 May 11.</citation>
    <PMID>16690331</PMID>
  </reference>
  <reference>
    <citation>Cooper DN, Krawczak M. The mutational spectrum of single base-pair substitutions causing human genetic disease: patterns and predictions. Hum Genet. 1990 Jun;85(1):55-74. Review.</citation>
    <PMID>2192981</PMID>
  </reference>
  <reference>
    <citation>Zhang ZP, Lindstedt M, Falk G, Blombäck M, Egberg N, Anvret M. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am J Hum Genet. 1992 Oct;51(4):850-8.</citation>
    <PMID>1415226</PMID>
  </reference>
  <reference>
    <citation>Eikenboom JC, Ploos van Amstel HK, Reitsma PH, Briët E. Mutations in severe, type III von Willebrand's disease in the Dutch population: candidate missense and nonsense mutations associated with reduced levels of von Willebrand factor messenger RNA. Thromb Haemost. 1992 Oct 5;68(4):448-54.</citation>
    <PMID>1448779</PMID>
  </reference>
  <reference>
    <citation>Bahnak BR, Lavergne JM, Rothschild C, Meyer D. A stop codon in a patient with severe type III von Willebrand disease. Blood. 1991 Aug 15;78(4):1148-9.</citation>
    <PMID>1868248</PMID>
  </reference>
  <reference>
    <citation>Zhang ZP, Falk G, Blombäck M, Egberg N, Anvret M. Identification of a new nonsense mutation in the von Willebrand factor gene in patients with von Willebrand disease type III. Hum Mol Genet. 1992 Apr;1(1):61-2.</citation>
    <PMID>1301136</PMID>
  </reference>
  <reference>
    <citation>Zhang ZP, Blombäck M, Egberg N, Falk G, Anvret M. Characterization of the von Willebrand factor gene (VWF) in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin. Genomics. 1994 May 1;21(1):188-93.</citation>
    <PMID>8088787</PMID>
  </reference>
  <reference>
    <citation>Hagiwara T, Inaba H, Yoshida S, Nagaizumi K, Arai M, Hanabusa H, Fukutake K. A novel mutation Gly 1672--&gt;Arg in type 2A and a homozygous mutation in type 2B von Willebrand disease. Thromb Haemost. 1996 Aug;76(2):253-7.</citation>
    <PMID>8865541</PMID>
  </reference>
  <reference>
    <citation>Gupta PK, Saxena R, Adamtziki E, Budde U, Oyen F, Obser T, Schneppenheim R. Genetic defects in von Willebrand disease type 3 in Indian and Greek patients. Blood Cells Mol Dis. 2008 Sep-Oct;41(2):219-22. doi: 10.1016/j.bcmd.2008.03.004. Epub 2008 May 16.</citation>
    <PMID>18485763</PMID>
  </reference>
  <reference>
    <citation>Casaña P, Martínez F, Haya S, Lorenzo JI, Espinós C, Aznar JA. Q1311X: a novel nonsense mutation of putative ancient origin in the von Willebrand factor gene. Br J Haematol. 2000 Nov;111(2):552-5.</citation>
    <PMID>11122100</PMID>
  </reference>
  <reference>
    <citation>Surdhar GK, Enayat MS, Lawson S, Williams MD, Hill FG. Homozygous gene conversion in von Willebrand factor gene as a cause of type 3 von Willebrand disease and predisposition to inhibitor development. Blood. 2001 Jul 1;98(1):248-50.</citation>
    <PMID>11439975</PMID>
  </reference>
  <reference>
    <citation>Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, Mannucci PM. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis. 2003 May-Jun;30(3):264-70.</citation>
    <PMID>12737944</PMID>
  </reference>
  <reference>
    <citation>Gupta PK, Adamtziki E, Budde U, Jaiprakash M, Kumar H, Harbeck-Seu A, Kannan M, Oyen F, Obser T, Wedekind I, Saxena R, Schneppenheim R. Gene conversions are a common cause of von Willebrand disease. Br J Haematol. 2005 Sep;130(5):752-8.</citation>
    <PMID>16115133</PMID>
  </reference>
  <reference>
    <citation>Eikenboom JC, Vink T, Briët E, Sixma JJ, Reitsma PH. Multiple substitutions in the von Willebrand factor gene that mimic the pseudogene sequence. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2221-4.</citation>
    <PMID>8134377</PMID>
  </reference>
  <reference>
    <citation>Zhang ZP, Falk G, Blombäck M, Egberg N, Anvret M. A single cytosine deletion in exon 18 of the von Willebrand factor gene is the most common mutation in Swedish vWD type III patients. Hum Mol Genet. 1992 Dec;1(9):767-8.</citation>
    <PMID>1302613</PMID>
  </reference>
  <reference>
    <citation>Xie F, Wang X, Cooper DN, Lan F, Fang Y, Cai X, Wang Z, Wang H. Compound heterozygosity for two novel mutations (1203insG/Y1456X) in the von Willebrand factor gene causing type 3 von Willebrand disease. Haemophilia. 2007 Sep;13(5):645-8.</citation>
    <PMID>17880457</PMID>
  </reference>
  <reference>
    <citation>Wetzstein V, Budde U, Oyen F, Ding X, Herrmann J, Liebig B, Schneppenheim R. Intracranial hemorrhage in a term newborn with severe von Willebrand disease type 3 associated with sinus venous thrombosis. Haematologica. 2006 Dec;91(12 Suppl):ECR60.</citation>
    <PMID>17194666</PMID>
  </reference>
  <reference>
    <citation>Krawczak M, Cooper DN. Gene deletions causing human genetic disease: mechanisms of mutagenesis and the role of the local DNA sequence environment. Hum Genet. 1991 Mar;86(5):425-41.</citation>
    <PMID>2016084</PMID>
  </reference>
  <reference>
    <citation>Efstratiadis A, Posakony JW, Maniatis T, Lawn RM, O'Connell C, Spritz RA, DeRiel JK, Forget BG, Weissman SM, Slightom JL, Blechl AE, Smithies O, Baralle FE, Shoulders CC, Proudfoot NJ. The structure and evolution of the human beta-globin gene family. Cell. 1980 Oct;21(3):653-68.</citation>
    <PMID>6985477</PMID>
  </reference>
  <reference>
    <citation>Zhang ZP, Blombäck M, Nyman D, Anvret M. Mutations of von Willebrand factor gene in families with von Willebrand disease in the Aland Islands. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7937-40.</citation>
    <PMID>8367445</PMID>
  </reference>
  <reference>
    <citation>Mohlke KL, Nichols WC, Rehemtulla A, Kaufman RJ, Fagerström HM, Ritvanen KL, Kekomăki R, Ginsburg D. A common frameshift mutation in von Willebrand factor does not alter mRNA stability but interferes with normal propeptide processing. Br J Haematol. 1996 Oct;95(1):184-91.</citation>
    <PMID>8857958</PMID>
  </reference>
  <reference>
    <citation>Eikenboom JC, Reitsma PH, van der Velden PA, Briët E. Instability of repeats of the von Willebrand factor gene variable number tandem repeat sequence in intron 40. Br J Haematol. 1993 Jul;84(3):533-5.</citation>
    <PMID>8105872</PMID>
  </reference>
  <reference>
    <citation>Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat. 1998;11(1):1-3.</citation>
    <PMID>9450896</PMID>
  </reference>
  <reference>
    <citation>Mertes G, Ludwig M, Finkelnburg B, Krawczak M, Schwaab R, Brackmann HH, Olek K. A G+3-to-T donor splice site mutation leads to skipping of exon 50 in von Willebrand factor mRNA. Genomics. 1994 Nov 1;24(1):190-1.</citation>
    <PMID>7896280</PMID>
  </reference>
  <reference>
    <citation>Zhang Z, Lindstedt M, Blombäck M, Anvret M. Effects of the mutant von Willebrand factor gene in von Willebrand disease. Hum Genet. 1995 Oct;96(4):388-94.</citation>
    <PMID>7557958</PMID>
  </reference>
  <reference>
    <citation>Allen S, Abuzenadah AM, Hinks J, Blagg JL, Gursel T, Ingerslev J, Goodeve AC, Peake IR, Daly ME. A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. Blood. 2000 Jul 15;96(2):560-8.</citation>
    <PMID>10887119</PMID>
  </reference>
  <reference>
    <citation>Castaman G, Lattuada A, Mannucci PM, Rodeghiero F. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. Br J Haematol. 1995 Jan;89(1):147-51.</citation>
    <PMID>7833254</PMID>
  </reference>
  <reference>
    <citation>Tjernberg P, Castaman G, Vos HL, Bertina RM, Eikenboom JC. Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease. Br J Haematol. 2006 May;133(4):409-18.</citation>
    <PMID>16643449</PMID>
  </reference>
  <reference>
    <citation>Castaman G, Eikenboom JC, Lattuada A, Mannucci PM, Rodeghiero F. Heightened proteolysis of the von Willebrand factor subunit in patients with von Willebrand disease hemizygous or homozygous for the C2362F mutation. Br J Haematol. 2000 Jan;108(1):188-90.</citation>
    <PMID>10651743</PMID>
  </reference>
  <reference>
    <citation>Baronciani L, Federici AB, Cozzi G, La Marca S, Punzo M, Rubini V, Canciani MT, Mannucci PM. Expression studies of missense mutations p.D141Y, p.C275S located in the propeptide of von Willebrand factor in patients with type 3 von Willebrand disease. Haemophilia. 2008 May;14(3):549-55. doi: 10.1111/j.1365-2516.2008.01682.x. Epub 2008 Mar 4.</citation>
    <PMID>18328061</PMID>
  </reference>
  <reference>
    <citation>Voorberg J, Fontijn R, Calafat J, Janssen H, van Mourik JA, Pannekoek H. Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids. J Cell Biol. 1991 Apr;113(1):195-205.</citation>
    <PMID>2007623</PMID>
  </reference>
  <reference>
    <citation>Peake IR, Bowen D, Bignell P, Liddell MB, Sadler JE, Standen G, Bloom AL. Family studies and prenatal diagnosis in severe von Willebrand disease by polymerase chain reaction amplification of a variable number tandem repeat region of the von Willebrand factor gene. Blood. 1990 Aug 1;76(3):555-61.</citation>
    <PMID>2378985</PMID>
  </reference>
  <reference>
    <citation>Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilbert L, Mannucci PM. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004 Mar 15;103(6):2032-8. Epub 2003 Nov 20.</citation>
    <PMID>14630825</PMID>
  </reference>
  <reference>
    <citation>Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, Rodeghiero F. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008 Apr 1;111(7):3531-9. doi: 10.1182/blood-2007-08-109231. Epub 2008 Jan 29.</citation>
    <PMID>18230755</PMID>
  </reference>
  <reference>
    <citation>Cattaneo M, Moia M, Delle Valle P, Castellana P, Mannucci PM. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. Blood. 1989 Nov 1;74(6):1972-5.</citation>
    <PMID>2508791</PMID>
  </reference>
  <reference>
    <citation>Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, Retzios AD, Kapelan BA, Schwartz RS, Kessler C; Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood. 2002 Jan 15;99(2):450-6.</citation>
    <PMID>11781224</PMID>
  </reference>
  <reference>
    <citation>Federici AB, Baudo F, Caracciolo C, Mancuso G, Mazzucconi MG, Musso R, Schinco PC, Targhetta R, Mannuccio Mannucci P. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia. 2002 Nov;8(6):761-7.</citation>
    <PMID>12410644</PMID>
  </reference>
  <reference>
    <citation>Bello IF, Yuste VJ, Molina MQ, Navarro FH. Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. Haemophilia. 2007 Dec;13 Suppl 5:25-32. doi: 10.1111/j.1365-2516.2007.01570.x.</citation>
    <PMID>18078394</PMID>
  </reference>
  <reference>
    <citation>Federici AB, Barillari G, Zanon E, Mazzucconi MG, Musso R, Targhetta R, Mannucci PM. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia. 2010 Jan;16(1):101-10. doi: 10.1111/j.1365-2516.2009.02088.x. Epub 2009 Oct 6.</citation>
    <PMID>19811543</PMID>
  </reference>
  <reference>
    <citation>Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia. 1998;4 Suppl 3:33-9.</citation>
    <PMID>10028316</PMID>
  </reference>
  <reference>
    <citation>Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA; Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002 Feb;87(2):224-30.</citation>
    <PMID>11858481</PMID>
  </reference>
  <reference>
    <citation>Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica. 2003 Nov;88(11):1279-83.</citation>
    <PMID>14607757</PMID>
  </reference>
  <reference>
    <citation>Federici AB, Castaman G, Franchini M, Morfini M, Zanon E, Coppola A, Tagliaferri A, Boeri E, Mazzucconi MG, Rossetti G, Mannucci PM. Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica. 2007 Jul;92(7):944-51.</citation>
    <PMID>17606445</PMID>
  </reference>
  <reference>
    <citation>Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA; Humate-P Study Group. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia. 2003 Nov;9(6):688-95.</citation>
    <PMID>14750934</PMID>
  </reference>
  <reference>
    <citation>Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA; Humate-P Study Group. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia. 2004 Jan;10(1):42-51.</citation>
    <PMID>14962219</PMID>
  </reference>
  <reference>
    <citation>Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM; HAEMATE P Surgical Study Group. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost. 2007 Jul;5(7):1420-30. Epub 2007 Apr 16.</citation>
    <PMID>17439628</PMID>
  </reference>
  <reference>
    <citation>Stadler M, Gruber G, Kannicht C, Biesert L, Radomski KU, Suhartono H, Pock K, Neisser-Svae A, Weinberger J, Römisch J, Svae TE. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate). Biologicals. 2006 Dec;34(4):281-8. Epub 2006 Feb 23.</citation>
    <PMID>16500114</PMID>
  </reference>
  <reference>
    <citation>Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. Thromb Haemost. 2007 Jun;97(6):922-30.</citation>
    <PMID>17549293</PMID>
  </reference>
  <reference>
    <citation>Shortt J, Dunkley S, Rickard K, Baker R, Street A. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures. Haemophilia. 2007 Mar;13(2):144-8.</citation>
    <PMID>17286766</PMID>
  </reference>
  <reference>
    <citation>Menache D, Aronson DL, Darr F, Montgomery RR, Gill JC, Kessler CM, Lusher JM, Phatak PD, Shapiro AD, Thompson AR, White GC 2nd. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. Br J Haematol. 1996 Sep;94(4):740-5.</citation>
    <PMID>8826903</PMID>
  </reference>
  <reference>
    <citation>Goudemand J, Scharrer I, Berntorp E, Lee CA, Borel-Derlon A, Stieltjes N, Caron C, Scherrmann JM, Bridey F, Tellier Z, Federici AB, Mannucci PM. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost. 2005 Oct;3(10):2219-27.</citation>
    <PMID>16194199</PMID>
  </reference>
  <reference>
    <citation>Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost. 2007 Jun;5(6):1115-24.</citation>
    <PMID>17403090</PMID>
  </reference>
  <reference>
    <citation>Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med. 1995 Mar;125(3):348-55.</citation>
    <PMID>7897302</PMID>
  </reference>
  <reference>
    <citation>Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis. 1996;26 Suppl 1:150-4.</citation>
    <PMID>8904191</PMID>
  </reference>
  <reference>
    <citation>Boyer-Neumann C, Dreyfus M, Wolf M, Veyradier A, Meyer D. Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease. J Thromb Haemost. 2003 Jan;1(1):190-2.</citation>
    <PMID>12871560</PMID>
  </reference>
  <reference>
    <citation>Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis. 2005 Apr;16 Suppl 1:S23-6. Review.</citation>
    <PMID>15849523</PMID>
  </reference>
  <reference>
    <citation>De Meyer SF, Vanhoorelbeke K, Chuah MK, Pareyn I, Gillijns V, Hebbel RP, Collen D, Deckmyn H, VandenDriessche T. Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood. 2006 Jun 15;107(12):4728-36. Epub 2006 Feb 14.</citation>
    <PMID>16478886</PMID>
  </reference>
  <reference>
    <citation>von Willebrand EA. (1926) Hereditär Pseudohemofili. Finska Läkaresällskapets Handlingar 68, 87-112.</citation>
  </reference>
  <reference>
    <citation>Federici AB, Bucciarelli P, Castaman G et al. (2007) Incidence and determinants of bleeding in different types of von Willebrand disease:results of the first prospective multicenter study on 814 Italian patients Blood 110, 713</citation>
  </reference>
  <reference>
    <citation>Abuzenadah AM, Gursel T, Ingerslev J et al. (1999) Mutational analysis of the von Willebrand factor gene in 27 families from Turkey with von Willebrand disease Thromb Haemost 82 (Suppl), 283</citation>
  </reference>
  <reference>
    <citation>Castaman G, Giacomelli SH, Coppola A et al. (2008) Molecular bases of type 3 von Willebrand disease in Italy: report on 12 families Blood Transfus Suppl 3, 44</citation>
  </reference>
  <reference>
    <citation>Gazda H, Budde U, Krey S et al. (1997) Delta C in exon 18 of the von Willebrand factor gene is the most common mutation in patients with severe von Willebrand disease type 3 in Poland Blood 90 (Suppl 1), 94b</citation>
  </reference>
  <reference>
    <citation>Titapiwatanakun R, Guenther JC, Asmann YW et al. (2007) Novel Mutations in Types 2 &amp; 3 von Willebrand Disease and Correlation with von Willebrand Factor Multimer Patterns. Blood 110, 2136</citation>
  </reference>
  <reference>
    <citation>Montgomery RR, Jozwiak MA, Hutter JJ et al. (1999) A homozygous variant of the von Willebrand factor (VWF) that fails to c-terminal dimerize resulting in loss of VWF multimers larger than dimer Blood 94 (Suppl 1), 443a</citation>
  </reference>
  <reference>
    <citation>Schneppenheim R, Budde U, Drewke E et al. (1999) Cysteine mutations of von Willebrand factor correlate with different types of von Willebrand disease Thromb Haemost 82 (Suppl), 283</citation>
  </reference>
  <reference>
    <citation>Enayat MS, Guilliatt AM, Surdhar GK et al. (2001) Identification of five novel mutations in families with type 3 von Willebrand's disease Thromb Haemost 86 (Suppl), P1810</citation>
  </reference>
  <reference>
    <citation>Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med. 2004 Aug 12;351(7):683-94. Review.</citation>
    <PMID>15306670</PMID>
  </reference>
  <reference>
    <citation>Federici AB, Gianniello F, Canciani MT et al. (2005) Secondary long-term prophylaxis in severe patients with von Willebrand disease: an Italian cohort study Blood 106, 507a</citation>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <results_first_submitted>February 3, 2016</results_first_submitted>
  <results_first_submitted_qc>March 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 19, 2016</results_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor VIII</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>von Willebrand Diseases</keyword>
  <keyword>von Willebrand Factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
    <mesh_term>Von Willebrand Disease, Type 3</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Type 3 VWD</title>
          <description>Diagnosis of Type 3 von Willebrand Disease</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Retrospective Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Confirmatory Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Information not yet available.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="266"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Prospective Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Information not yet available.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Information not yet available.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study population should include a cohort of at least 250 patients with diagnosis of Type 3 Von Willebrand Disease enrolled using homogeneous and standardized criteria.</population>
      <group_list>
        <group group_id="B1">
          <title>Type 3 VWD</title>
          <description>Diagnosis of Type 3 von Willebrand Disease</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="266"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.13534" spread="18.22409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iran, Islamic Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bleeding Severity Score (BSS)</title>
        <description>The range of measurement is from -1 to +4 for each symptom considered (12 symptoms, total range from -12 to 48). For each symptom: 0=no symptom, 1=referred by the patient, 2=brought to medical attention, 3=major intervention. For spontaneous hemorrhagic symptoms, scores equal or greater than two require that the patient has specifically addressed that hemorrhagic symptom with a physician, whatever has been the diagnosis and therapy subsequently proposed. Score 0 and 1 are attributed to symptoms referred by the patient, hence without any precise medical intervention. Score 0 is for negligible or absent symptoms; 1 otherwise. For surgical procedures, it is considered important to differentiate between patients that have never bled because they never underwent surgery and those that did not bled after a surgery. These latter receive a negative score, indicating that the probability of VWD diminishes if you don’t bleed after surgery.</description>
        <time_frame>24 months (retrospective phase)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Type 3 VWD</title>
            <description>Diagnosis of Type 3 von Willebrand Disease</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Severity Score (BSS)</title>
          <description>The range of measurement is from -1 to +4 for each symptom considered (12 symptoms, total range from -12 to 48). For each symptom: 0=no symptom, 1=referred by the patient, 2=brought to medical attention, 3=major intervention. For spontaneous hemorrhagic symptoms, scores equal or greater than two require that the patient has specifically addressed that hemorrhagic symptom with a physician, whatever has been the diagnosis and therapy subsequently proposed. Score 0 and 1 are attributed to symptoms referred by the patient, hence without any precise medical intervention. Score 0 is for negligible or absent symptoms; 1 otherwise. For surgical procedures, it is considered important to differentiate between patients that have never bled because they never underwent surgery and those that did not bled after a surgery. These latter receive a negative score, indicating that the probability of VWD diminishes if you don’t bleed after surgery.</description>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="1" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>General Laboratory Tests for VWD3 Diagnosis (Composite)</title>
        <description>Hemoglobin: (mmol/L), HT(%), MVC (fl); Leucocytes: (E9/L); Neutrophil (%); Basophil (%); Eosinophil (%); Lymphocyte (%); Platelet count: (E9/L), MPV (fl); Prothrombin Time (sec); PTT (sec); PTT mix 50:50 (sec); Ferritin (ug/l); Bleeding Time (min:sec); Closure Time (Sec); Collagen/ADP (sec); Collagen/Epinephrine (sec); FVIII:C (IU/mL); VWF:RCo (IU/mL); VWF:Ag (IU/mL).</description>
        <time_frame>36 months (retrospective + confirmatory phase)</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Test for Anti-VWF Antibodies</title>
        <description>Evaluation of the titre of Anti-VWF Antibodies through Bethesda test (BU).</description>
        <time_frame>36 months (retrospective + confirmatory phase)</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Molecular Diagnosis of VWF in DNA</title>
        <description>Evaluation of the presence of VWF gene defects (confirmation or screening for the first time).</description>
        <time_frame>36 months (retrospective + confirmatory phase)</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Previous Use of Blood Products</title>
        <description>Record of any product used in the previous 24 months (collected type of blood products/VWF concentrate, year of first exposure, units used).</description>
        <time_frame>24 months (retrospective)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Type 3 VWD</title>
            <description>Diagnosis of Type 3 von Willebrand Disease</description>
          </group>
        </group_list>
        <measure>
          <title>Previous Use of Blood Products</title>
          <description>Record of any product used in the previous 24 months (collected type of blood products/VWF concentrate, year of first exposure, units used).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Packed red cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cryoprecipitates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fresh frozen plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet concentrates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Allergic Reactions During Use of VWF-containing Concentrates</title>
        <description>Record of any allergic and anaphilactic reactions occurred in the past due to the use of any VWF concentrate and the date of onset.</description>
        <time_frame>24 months (retrospective)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Type 3 VWD</title>
            <description>Diagnosis of Type 3 von Willebrand Disease</description>
          </group>
        </group_list>
        <measure>
          <title>Allergic Reactions During Use of VWF-containing Concentrates</title>
          <description>Record of any allergic and anaphilactic reactions occurred in the past due to the use of any VWF concentrate and the date of onset.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Record of Bleeding Episodes</title>
        <description>Bleeding: severity, start date, stop date; Treatment: Product name, start date, stop date, Total IU, Total ED.</description>
        <time_frame>24 months (prospective phase)</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Record of all adverse events occurred during the prospective phase of the study.</description>
        <time_frame>24 months (prospective phase)</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Type of VWF/FVIII-containing Concentrates in Use</title>
        <description>Record of any VWF/FVIII-containing concentrates used and currently in use, including the current schedule type of treatment.</description>
        <time_frame>24 months (prospective phase)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data about adverse events occurring to participants will be collected throughout the whole study period (retrospective phase + prospective phase).</time_frame>
      <desc>For AE associated with treatments, Investigators are encouraged to contact the manufacturer / regulatory authorities to report it, and to share a copy of any form submitted with Sponsor. An Independent Data Monitoring Committee (DMC) will be appointed for data monitoring on safety.</desc>
      <group_list>
        <group group_id="E1">
          <title>Type 3 VWD</title>
          <description>Diagnosis of Type 3 von Willebrand Disease</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Augusto B. Federici</name_or_title>
      <organization>Hematology and Transfusion Medicine, L. Sacco University Hospital Department of Clinical &amp; Community Sciences, University of Milan, Via Pace, 9 20122 Milan, Italy</organization>
      <phone>+39-0250319895</phone>
      <email>augusto.federici@unimi.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

